NextCure (NXTC) to Release Earnings on Thursday

NextCure (NASDAQ:NXTC) is expected to release its earnings data before the market opens on Thursday, March 20th. Analysts expect NextCure to post earnings of ($0.35) per share for the quarter.

NextCure (NASDAQ:NXTC) last announced its quarterly earnings data on Thursday, March 6th. The company reported ($0.41) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.07). On average, analysts expect NextCure to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

NextCure Stock Performance

NXTC stock opened at $0.64 on Tuesday. The firm has a fifty day moving average price of $0.77 and a 200 day moving average price of $1.08. NextCure has a fifty-two week low of $0.64 and a fifty-two week high of $2.57. The firm has a market cap of $17.94 million, a PE ratio of -0.31 and a beta of 0.71.

Analysts Set New Price Targets

Separately, HC Wainwright restated a “buy” rating and issued a $3.00 price target on shares of NextCure in a research report on Monday.

About NextCure

NextCure, Inc, a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company is developing NC410, an immunomedicine designed to block immune suppression mediated by LAIR-1; NC762, a monoclonal antibody that binds specifically to B7-H4, a protein expressed on multiple tumor types; and NC525, a monoclonal antibody that binds to LAIR-1 to functionally kill AML blast cells and leukemic stem cells while preserving normal blood cells, including hematopoietic stem cells.